Draconis Pharma has got access to European funds through the support of “Ministerio de economia y competividad” of Spain, under the program “Retos de Colaboración” to develop the following projects:


Discovery and development of novel modulators of adenosin receptors for treatment of respiratory diseases.
Consortium integrated by: Palobiofarma, Fundació Hospital de la Santa Creu i Sant Pau and Draconis Pharma


Technological platform for development of knowledge related to drug-like properties and experimental tools for discovery of new compounds for treatment of dermatological disorders.
Consortium integrated by: Almirall, CSIC and Draconis Pharma.


ACINETOCLINIC is focused on completing the transition to human clinical development stage (Phase I in healthy volunteers) of the first universal vaccine against infections caused by the antibiotic-resistant bacterium Acinetobacter baumannii.
ACINETOCLINIC is funded by the 2016 RETOS-COLABORACIÓN program of the Ministry of Economy, Industry and Competitiveness and co-financed by the FEDER

mail enisa